A ‘next generation’ vaccine for malaria has shown success in its first human trial. The phase 1 study saw a strong immune response in 10 healthy volunteers. The vaccine was created by genetically engineering the malaria parasite to make it weaker. Scientist removed the three genes needed for it to successfully infect and cause disease in humans. None of the participants developed malaria symptoms, and showed a strong protective antibody response.
Jan 5, 2017
- With 1,300 jobs on offer, India remains Amazon's jobs hot spot
- Etihad Airways to invest in debt-laden Jet Airways at discounted Rs 150 per share
- Cheer for Vodafone Idea employees; salaries to be raised first time after 2017
- Yes Bank shares rise 5% on reports that Deutsche Bank India head leads CEO race
- Reliance Industries joins blockchain platform VAKT in digital push